论文部分内容阅读
目的 探讨骨肉瘤组织中胎盘型谷胱甘肽 S 转移酶 (GST π)和DNA拓朴酶Ⅱ (TopoⅡ )的表达及其与预后的关系。方法 应用免疫组化SP法检测GST π、TopoⅡ在 40例骨肉瘤中的表达 ,并结合临床资料分析其对预后的影响。结果 40例骨肉瘤中GST π和TopoⅡ的阳性表达率分别为 82 5 % (3 3 40 )和 5 2 5 % (2 1 40 ) ,其中术前化疗组TopoⅡ阳性表达率为 3 8 5 % (5 13 ) ,显著低于术前无化疗组 77 8% (2 1 2 7) (P <0 0 5 ) ,GST π的阳性表达率在两组间无显著差异 ;GST π和TopoⅡ的阳性表达率与患者的预后显著相关。结论 GST π主要参与骨肉瘤原发性耐药 ,TopoⅡ不仅参与骨肉瘤原发性耐药 ,同时也参与骨肉瘤继发性耐药 ;GST π和TopoⅡ是影响骨肉瘤预后的重要因素 ,可能成为评估骨肉瘤预后的有价值的指标。
Objective To investigate the expression of placental glutathione S-transferase (GST π) and Topo Ⅱ in osteosarcoma and its relationship with prognosis. Methods Immunohistochemical SP method was used to detect the expression of GST π and Topo Ⅱ in 40 cases of osteosarcoma. Combined with clinical data, the effect of GST π and Topo Ⅱ on the prognosis was analyzed. Results The positive expression rates of GST π and Topo Ⅱ in 40 cases of osteosarcoma were 82 5% (3 3 40) and 52 5% (2 1 40), respectively. The positive rate of Topo Ⅱ in preoperative chemotherapy group was 38.5% 5 13), which was significantly lower than 77 8% (2 1 2 7) (P 0 05) in the non-chemotherapy group before surgery. The positive expression rate of GST π had no significant difference between the two groups. The positive expression of GST π and TopoⅡ The rate is significantly related to the patient’s prognosis. Conclusion GST π is mainly involved in the primary drug resistance of osteosarcoma. Topo Ⅱ not only participates in the primary drug resistance of osteosarcoma, but also participates in the secondary drug resistance of osteosarcoma. GST π and Topo Ⅱ are the important factors affecting the prognosis of osteosarcoma and may become Evaluation of prognosis of osteosarcoma is a valuable indicator.